SlideShare a Scribd company logo
Sexually Transmitted Infections
Mike Guyton, MD
Assistant Clinical Professor/Academic
Faculty in General Pediatrics
Reportable STI’s in SC (2014)
• Chancroid
• Chlamydia trachomatis, genital site
• Gonorrhea (include susceptibility profile)
• (URGENT) Acute Hepatitis (A-E)
• Chronic Hepatitis (B-D)
• Hepatitis B Surface Antigen + with each pregnancy
• HIV and AIDS Clinical Diagnosis and positive test
results*
• Lymphogranuloma Venereum
• (URGENT) Syphilis (congenital, primary, secondary,
latent, tertiary, positive test
STI’s in the US
• The US ranks first among developed nations in the rate of STI’s
– In addition to teen pregnancies
• 24% of adolescent females (14-19) have lab evidence of at least 1/5
STI’s
– HPV (18%)
– Chlamydia (4%)
– Trichomonas (3%)
– HSV 2 (2%)
– Gonorrhea
• Repeated STI infection is a recognized risk factor for development of
HIV infection
– 3X higher in students with h/o multiple gonorrhea infections vs. no
infections
Quick CDC Facts
• FACT: 19 million new infections occur every year in the US
• FACT: STI’s cost the US HealthCare System $17 billion yearly
• FACT: Untreated STI’s cause 24,000 women in the US to
become infertile yearly
• FACT: While young people only represent 25% of the
sexually experienced population in the US, they account for
almost 50% of newly diagnosed STI infections
• FACT: ~20% of adolescents fail to fill Rx for STI treatment
Specific To Adolescents
Risk Factors
• Behavioral
– Time elapsed since first
intercourse
– Multiple or new partners
– Inconsistent use of condoms
– Alcohol/drug use*
• Biologic
– Cervical ectopy/immaturity
– Low levels of sIgA
Unique Issues
• Self-consent for Dx and Tx
• Concerns about privacy and
confidentiality
• Pregnancy/fear of
pregnancy
• Self-treatment
• Preference to notify
partners themselves
Expedited Partner Therapy
• Approach where partners who test positive for
certain STI’s are given RX without previous
medical evaluation
• Recommended use from CDC since 2006
• Previously recommended for Gonorrhea and
Chlamydia; however Gonorrhea recs have
changed
– Difficult to give due to new recommendations for
ceftriaxone injection only!
• EPT is permissible in SC and NC
– Visit www.cdc.gov/std/ept/legal/default.htm
STI Clinical Patterns
• Discharge Syndromes
– Gonorrhea and Chlamydia
– Bacterial Vaginosis/Candidiasis
– Mycoplasma Genitalium
• Genital Ulcer Syndromes
– Herpes Simplex Virus
– Primary Syphilis
– Chancroid/Lymphogranuloma Venereum/ Granuloma Inguinale
• Pelvic Inflammatory Disease
• Dermatologic Syndromes
– HPV
– Secondary Syphilis
– Disseminated Gonococcal Infection
– Pediculosis Pubis
Chlamydia and Gonorrhea
• Chlamydia is the most common bacterial STI in men and women
– Cervicitis (not vaginitis) with menometrorrhagia
– Dysuria-Pyuria Syndrome
– PID
– Perihepatitis
– Proctitis
– Men: See Urethritis, Prostatitis, Proctitis, Epididymitis, Reactive
Arthritis (1%)
• Gonorrhea
– Similar to above, but also can see higher incidence of pharyngitis (1-
12%)
– While mucoprulent discharge common, asymptomatic cases also occur
(50% in women vs 10-15% in men)
Chlamydia and Gonorrhea: Treatment
• Gonorrhea:
– Ceftriaxone 250mg IM x 1 PLUS Azithromycin 1g po x 1 OR Doxycycline 100mg
po BID x 7 days
– Other:
• ceftizoxime 500 mg intramuscularly/ cefotaxime 500 mg
intramuscularly/cefoxitin 2 g intramuscularly PLUS Azithro or Doxy
• Oral Cefixime 400mg x 1 dose PLUS Azithro OR Doxy
• Azithromycin Monotherapy with 2g x 1 dose
• Chlamydia:
– Azithromycin 1g po x 1 dose
– Doxycycline 100mg po BID x 7 days
– Other:
• Ofloxacin 300 mg orally twice daily for seven days
• Levofloxacin 500 mg orally once daily for seven days
• Erythromycin/PCN if pregnant and intolerant to Azithro
Rescreening
• “Rescreen all adolescents infected with chlamydia or
gonorrhea 3 months after treatment, regardless of whether
they believe that their sex partners were treated.”
Bacterial Vaginosis/Candidiasis
• Bacterial Vaginosis:
– Most common cause of vaginal discharge in women of
childbearing age (40-50%); abnormal alteration of vaginal flora
– Tx: Metronidazole 500mg po BID x 7 days OR Metronidazole
Gel 0.75% qday x 5 days OR Clindamycin 2% cream qhs x 7 days
– Other
• Clindamycin 300mg po x 7 days; Clindamycin Ovule; Tinidazole
• Candidiasis:
– Common in healthy reproductive age women; less likely sexual
transmission; often clinical diagnosis
– Tx: Recommended: Fluconazole 150mg po x 1 dose or if
severe/complicated, 150mg po every 72h x 2-3 doses.
Mycoplasma Genitalium
• Causes Non-Gonococcal Urethritis in men and emerging cause of
cervicitis and PID in women
– 15-25% of cases of NGU in men
– 18-46% of cases of NCNGU in men
– Role in women not fully established
• Co-infections with other STI-causing organisms is highly reported
• Clinical:
– Men: usually symptomatic (as high as 70%) with discharge, balantitis,
or posthitis
– Women: usually asymptomatic or occur with symptoms of PID
• Treatment:
– Empiric: Azithromycin OR Doxycycline
– Targeted: Same as above; Moxifloxicin if persistent
infection/symptoms
PREP Question
• An 18-year-old woman has a 3-day history of fever, headache, and
painful sores in the genital area. The patient has no previous history
of genital lesions. Medical history is unremarkable, and her only
medication is an oral contraceptive agent. She does not use
condoms. On physical examination, temperature is 38.1 °C (100.6
°F); other vital signs are normal. There are no signs of meningismus.
Tender ulcerative lesions with a yellow crusted roof cover the labia
bilaterally and the vaginal introitus.
• A.) Chancroid
• B.) Genital Herpes Simplex Virus Infection
• C.) Primary Syphilis
• D.) Vulvovaginal Candidiasis
PREP Question
• An 18-year-old woman has a 3-day history of fever, headache, and
painful sores in the genital area. The patient has no previous history
of genital lesions. Medical history is unremarkable, and her only
medication is an oral contraceptive agent. She does not use
condoms. On physical examination, temperature is 38.1 °C (100.6
°F); other vital signs are normal. There are no signs of meningismus.
Tender ulcerative lesions with a yellow crusted roof cover the labia
bilaterally and the vaginal introitus.
• A.) Chancroid
• B.) Genital Herpes Simplex Virus Infection
• C.) Primary Syphilis
• D.) Vulvovaginal Candidiasis
Genital Herpes
• Belongs to the Genital Ulcer Syndromes
– HSV, T. pallidum, and H. ducreyi
• HSV2 is predominant, with increasing HSV1 genital
occurrence in females
• Lesions begin as vesicles, which then rupture to form
painful ulcers
– Usually occurring as clusters
• Occurs as a Primary Outbreak, Recurrent Outbreak,
and Latent Infection
– Primary outbreak last 2-3 weeks and often associated
with systemic symptoms (fever, malaise, dysuria)
– Recurrent Outbreaks usually are shorter, 7-12 days
• HSV has a high infectivity and high recurrence rate
– Infectivity 75-80% with active infection
– HSV1 Recurrence: 60%; HSV2 Recurrence: 90%
Genital Herpes: Treatment
• Treatment differs based on type of
infection
– Primary:
• Acyclovir 400mg po TID or 200mg po 5x/d x 7-
10 days
• Famciclovir 250mg TID x 7-10 days
• Valacyclovir 1g BID x 7-10 days
– Recurrent:
• Acyclovir 800mg TID x 2 days or BID x 5 days
• Famciclovir 1g BID x 1 day or 125mg BID x 5 days
• Valacyclovir 500mg BID x 3 days
– Suppression:
• Valacyclovir 1g po qday (can be 500mg daily if
<9 recurrences/year)
– 500mg BID if immunoompromised
Primary Syphilis
• After incubation, a
ulcerating, painless papule
occurs at site of inoculation;
heal 3-6 weeks later
• Usually singular, but can be
multiple in setting of HIV
• Associated with regional
mild-moderate bilateral LAN
• Secondary Syphilis can
occur weeks to months later
Syphilis: Treatment
• Primary, Secondary, or
Latent <1 year
– PCN G Benzathine 2.4
million units IM x 1
– Doxycycline 100mg po BID
x 7 days
• Jarish-Herxheimer
Reaction
– Acute febrile reaction with
HA and myalgias in first 24
hours of treatment
Chancroid/Lymphogranuloma
Venereum/Granuloma Inguinale
• Chancroid
– Haemophilus ducreyi, very uncommon in the US
– Papule  pustule  PAINFUL ulcers with fluctuant buboes (lymph nodes can
spontaneously rupture)
– Tx: Azithromycin 1g po x 1 OR Ceftriaxone 250mg IM x 1
• Lymphogranuloma Venereum
– L1, L2, and L3 serovars of Chlamydia; tropical and subtropical areas of the
world
– Spontaneously healing PAINLESS genital ulcer extension to regional lymph
nodes (groove sign)  fibrosis and stricture of anogenital tract
– Tx: Doxycycline 100mg po BID x 21 days OR Erythromycin/Azithromycin
• Granuloma Inguinale (Donovanosis)
– Uncommon, caused by Klebsiella granulomatis (PAINLESS ULCER[S])
– Tx: Doxycycline, Azithromycin, Cipro, Erythromycin, or Bactrim x 3 weeks
Pelvic Inflammatory Disease
• Acute infection of the upper genital tract of women
– Chlamydia, Gonorrhea, or Vaginal Flora organisms (Anaerobes and
GNR)
– RF for subsequent ectopic pregnancy and infertility
• Clinical Diagnosis of PID is often imprecise; need evaluation of risk
factors
– Lower Quadrant Abdominal Pain, acute in nature
– Abnormal uterine bleeding (1/3 of patients)
– New onset discharge, urethritis, Proctitis, fever (non-specific)
• Empiric Treatment often initiated if 1 out of three clinical findings
present (in the setting of abdominal pain):
– Cervical Motion Tenderness
– Uterine Tenderness
– Adnexal Tenderness
Pelvic Inflammatory Disease:
Treatment
Indications for Hospitalization
• Pregnancy
• Nonresponse/tolerance to po
medications
• Noncompliance
• Inability to take oral medications
• Severe clinical illness (high fever,
nausea, vomiting, severe
abdominal pain)
• Complicated PID with pelvic
abscess
• Possible need for surgical
intervention or diagnostic
exploration for alternative
etiology (e.g., appendicitis)
Outpatient vs Inpatient
• Outpatient:
– Ceftriaxone 250mg IM x 1 PLUS
Doxy 100mg po BID x 14 days
– Cefoxitin 2mg IM with
Probenecid 1g po x 1 PLUS
Doxy 100mg po BID x 14 days
• Inpatient:
– Cefoxitin (2g IV q6) OR
Cefotetan (2g IV q12) PLUS
Doxy100mg po q12
– Clindamycin 900mg IV q8 PLUS
Gentamicin (Load: 2mg/kg;
Maint: 1.5mg/kg q8)
Genital Warts
• Condyloma Accuminata, caused by Human Papilloma Virus
– >70 different subtypes; High risk associated with cancers (16, 18) and low risk associated with
genital warts (6, 11)
– Incubation is 3w-8m and most infections are cleared within 2 years
• Risk Factors
– Sexual activity (more partners increases the risk in Men and Women)
– Concomitant/history of recurrent STI’s
– Individuals who are HIV positive
• Clinical
– Ranges from asymptomatic (M and F) to problematic, depending on the size of warts
– Can see Pruritus, pain, bleeding, tenderness, or vaginal discharge
• Differential Diagnosis
– Condyloma Lata
– Micropapillomatosis
– Pearly Penile Papules
– Squamous Cell Carcinoma
Genital Warts: Treatment
• Multiple Modalities of Treatment
– Spontaneous Remission (20-30% of cases)
– Chemical Agents
• Podophyllin: Teratogenic, risk of chemical burns
• Trichloroacetic Acid: can be used internally, but highly caustic
• 5-Fluorouracil Epinephrine Gel: Injected Intralesionally
– Immune Modulation
• Imiquimod: Complete clearance rates of 40-70% with few recurrence
• Interferon Alfa: side effects of interferon
• Sinecatechins: botanical
– Surgery
• Cryotherapy, Laser, Excisional
– HPV Vaccination: highly effective
Secondary Syphilis
Disseminated Gonococcus
• 0.5-3% of those infected with Nisseria gonorrheae (M>F 3X)
• Certain Risk Factors Exist
– Recent menstruation, Pregnancy/immediate post-partum,
complement deficiencies, or SLE
• Clinical Findings:
– Triad: Tenosynovitis, dermatitis, polyarthralgias without purulent
arthritis
• Acute Fever, chills, malaise is heralding
• Lesions often painless, pustular or vesiculopustular
– Purulent arthritis without skin lesions
• Asymmetric, usually knees/wrists/ankles
• Treatment:
– Ceftriaxone 1g q24 hours initially PLUS Azithromycin 1g po x 1 OR
Doxycycline 100mg po BID x 7 days
– Duration: 7-14 days; step down therapy controversial
Disseminated Gonococcus
Pediculosis Pubis
• Crab Louse, transmitted through sex or sometimes Fomites
• Clinical:
– Itching
– Maculae Cerulae: pale blue macules (0.5-1cm) from the
anticoagulant present in saliva of parasite, prolonged infestation
– Sometimes LAN
• Treatment:
– Permethrin 1% cream applied and washed off after 10 minutes
– Pyrethrins with piperonyl butoxide, same as above
– Alternative
• Malathion 0.5% lotion applied and washed off after 8-12 hours
• Ivermectin 250mcg/kg orally x 1, repeated in 1-2 weeks
• Lindane not recommended
Which is Which?
A word on HIV screening
• Test: HIV Ag/Ab Combo
• CDC Recommendations:
– Opt-Out HIV testing for all patients 13-64 years old
• AAP Recommendations:
– Routine HIV testing to be offered at least once to all
adolescents (despite report of sexual activity) by 16-18yo
in clinic settings where HIV prevalence is >0.1%
– Prevalence <0.1%: HIV testing for all sexually active
adolescents and those with other risk factors
Questions?

More Related Content

What's hot

Vulvovaginal Infections,Vaginitis,Fmdrl3
Vulvovaginal Infections,Vaginitis,Fmdrl3Vulvovaginal Infections,Vaginitis,Fmdrl3
Vulvovaginal Infections,Vaginitis,Fmdrl3MedicineAndHealthUSA
 
Dysmenorrhea
DysmenorrheaDysmenorrhea
Vulvovaginitis
VulvovaginitisVulvovaginitis
Vulvovaginitis
Ahmed Nasef
 
UTI in Pregnancy
UTI in PregnancyUTI in Pregnancy
UTI in Pregnancy
bajah423
 
Sexually Transmitted Diseases
Sexually Transmitted DiseasesSexually Transmitted Diseases
Sexually Transmitted DiseasesMedicineAndHealth
 
Syndromic management of STD's
Syndromic management of STD'sSyndromic management of STD's
Syndromic management of STD'sSwetha Saravanan
 
Antenatal care
Antenatal careAntenatal care
Antenatal care
Dr Fahad Albedaiwi
 
Pelvic Inflammatory Disease with YouTube Video
Pelvic Inflammatory Disease with YouTube VideoPelvic Inflammatory Disease with YouTube Video
Pelvic Inflammatory Disease with YouTube Video
Karthikeyan Pethusamy
 
Tuberculosis and pregnancy
Tuberculosis and pregnancyTuberculosis and pregnancy
Tuberculosis and pregnancy
Khairul Jessy
 
HIV and PTB in pregnancy
HIV and PTB in pregnancyHIV and PTB in pregnancy
HIV and PTB in pregnancy
Helen Madamba
 
pyelonephritis in pregnancy
pyelonephritis in pregnancypyelonephritis in pregnancy
pyelonephritis in pregnancy
AaronAagii
 
Teenage Pregnancy
Teenage PregnancyTeenage Pregnancy
Teenage Pregnancy
Yaqeen Ul Haq Ahmad Sikander
 
Reproductive health 2020
Reproductive health 2020Reproductive health 2020
Reproductive health 2020
Mohammed aljradey
 
Infections in pregnancy
Infections in pregnancyInfections in pregnancy
Infections in pregnancy
Dhammike Silva
 
Drug use in pregnany
Drug use in pregnanyDrug use in pregnany
Drug use in pregnany
Dr B Naga Raju
 
GESTATIONAL DIABETES
GESTATIONAL DIABETESGESTATIONAL DIABETES
GESTATIONAL DIABETES
RISHIKESAN K V
 
STI'S
STI'SSTI'S
PELVIC INFLAMMATORY DISEASE
PELVIC INFLAMMATORY DISEASEPELVIC INFLAMMATORY DISEASE
PELVIC INFLAMMATORY DISEASEMoses Daodu
 
Case Discussion - Teen pregnancy
Case Discussion - Teen pregnancyCase Discussion - Teen pregnancy
Case Discussion - Teen pregnancy
Afiqi Fikri
 

What's hot (20)

Vulvovaginal Infections,Vaginitis,Fmdrl3
Vulvovaginal Infections,Vaginitis,Fmdrl3Vulvovaginal Infections,Vaginitis,Fmdrl3
Vulvovaginal Infections,Vaginitis,Fmdrl3
 
Dysmenorrhea
DysmenorrheaDysmenorrhea
Dysmenorrhea
 
Vulvovaginitis
VulvovaginitisVulvovaginitis
Vulvovaginitis
 
UTI in Pregnancy
UTI in PregnancyUTI in Pregnancy
UTI in Pregnancy
 
Sexually Transmitted Diseases
Sexually Transmitted DiseasesSexually Transmitted Diseases
Sexually Transmitted Diseases
 
Syndromic management of STD's
Syndromic management of STD'sSyndromic management of STD's
Syndromic management of STD's
 
Antenatal care
Antenatal careAntenatal care
Antenatal care
 
Pelvic Inflammatory Disease with YouTube Video
Pelvic Inflammatory Disease with YouTube VideoPelvic Inflammatory Disease with YouTube Video
Pelvic Inflammatory Disease with YouTube Video
 
Tuberculosis and pregnancy
Tuberculosis and pregnancyTuberculosis and pregnancy
Tuberculosis and pregnancy
 
HIV and PTB in pregnancy
HIV and PTB in pregnancyHIV and PTB in pregnancy
HIV and PTB in pregnancy
 
pyelonephritis in pregnancy
pyelonephritis in pregnancypyelonephritis in pregnancy
pyelonephritis in pregnancy
 
Vaginitis
VaginitisVaginitis
Vaginitis
 
Teenage Pregnancy
Teenage PregnancyTeenage Pregnancy
Teenage Pregnancy
 
Reproductive health 2020
Reproductive health 2020Reproductive health 2020
Reproductive health 2020
 
Infections in pregnancy
Infections in pregnancyInfections in pregnancy
Infections in pregnancy
 
Drug use in pregnany
Drug use in pregnanyDrug use in pregnany
Drug use in pregnany
 
GESTATIONAL DIABETES
GESTATIONAL DIABETESGESTATIONAL DIABETES
GESTATIONAL DIABETES
 
STI'S
STI'SSTI'S
STI'S
 
PELVIC INFLAMMATORY DISEASE
PELVIC INFLAMMATORY DISEASEPELVIC INFLAMMATORY DISEASE
PELVIC INFLAMMATORY DISEASE
 
Case Discussion - Teen pregnancy
Case Discussion - Teen pregnancyCase Discussion - Teen pregnancy
Case Discussion - Teen pregnancy
 

Viewers also liked

Sexperts sti lecture ucaya
Sexperts sti lecture ucayaSexperts sti lecture ucaya
Sexperts sti lecture ucaya
Greenville Health System
 
Common Skin Disorders Of The Penis
Common Skin Disorders Of The PenisCommon Skin Disorders Of The Penis
Common Skin Disorders Of The Penis
Ahmad Kharrouby
 
Stds
StdsStds
Stds
akifab93
 
Sexually transmitted infections Part VI
Sexually transmitted infections Part VISexually transmitted infections Part VI
Sexually transmitted infections Part VI
Carmela Domocmat
 
Female STD/STI Presentation
Female STD/STI PresentationFemale STD/STI Presentation
Female STD/STI Presentation
Hawaii Holloway
 
Chancroid
ChancroidChancroid
Chancroid
iPROVIBE
 
Granuloma inguinale, lymphogranuloma venereum, gonorrhea
Granuloma inguinale, lymphogranuloma venereum, gonorrheaGranuloma inguinale, lymphogranuloma venereum, gonorrhea
Granuloma inguinale, lymphogranuloma venereum, gonorrhea
hanisahwarrior
 
Genital ulcer
Genital ulcerGenital ulcer
Genital ulcer
Dr Daulatram Dhaked
 
Dermatology made easy
Dermatology made easyDermatology made easy
Dermatology made easy
Daniel Augustine
 
Common skin infections
Common skin infectionsCommon skin infections
Common skin infections
MEEQAT HOSPITAL
 
Dermatology osce slides
Dermatology osce slidesDermatology osce slides
Dermatology osce slidesHabrol Afzam
 
Sexually transmitted diseases (pictures)
Sexually transmitted diseases (pictures)Sexually transmitted diseases (pictures)
Sexually transmitted diseases (pictures)
Reynel Dan
 
Presentaciòn Mycoplasma
Presentaciòn MycoplasmaPresentaciòn Mycoplasma
Presentaciòn Mycoplasma
Universidad "Andres Bello"
 
Clamídia
ClamídiaClamídia
Clamídia
olgacacao
 
Mycoplasma complete
Mycoplasma completeMycoplasma complete
Mycoplasma complete
Dr. Kanwal Deep Singh Lyall
 
Treponema Pallidum - Microbiología
Treponema Pallidum - MicrobiologíaTreponema Pallidum - Microbiología
Treponema Pallidum - Microbiología
Hektor Valkyrie Eguía
 
5 Cures for Chlamydia You Should Know!
5 Cures for Chlamydia You Should Know!5 Cures for Chlamydia You Should Know!
5 Cures for Chlamydia You Should Know!
RNAdvisor
 

Viewers also liked (20)

Sexperts sti lecture ucaya
Sexperts sti lecture ucayaSexperts sti lecture ucaya
Sexperts sti lecture ucaya
 
Ngu
NguNgu
Ngu
 
Common Skin Disorders Of The Penis
Common Skin Disorders Of The PenisCommon Skin Disorders Of The Penis
Common Skin Disorders Of The Penis
 
Stds
StdsStds
Stds
 
Sexually transmitted infections Part VI
Sexually transmitted infections Part VISexually transmitted infections Part VI
Sexually transmitted infections Part VI
 
Female STD/STI Presentation
Female STD/STI PresentationFemale STD/STI Presentation
Female STD/STI Presentation
 
Chancroid
ChancroidChancroid
Chancroid
 
Granuloma inguinale, lymphogranuloma venereum, gonorrhea
Granuloma inguinale, lymphogranuloma venereum, gonorrheaGranuloma inguinale, lymphogranuloma venereum, gonorrhea
Granuloma inguinale, lymphogranuloma venereum, gonorrhea
 
Genital ulcer
Genital ulcerGenital ulcer
Genital ulcer
 
Dermatology made easy
Dermatology made easyDermatology made easy
Dermatology made easy
 
Common skin infections
Common skin infectionsCommon skin infections
Common skin infections
 
Dermatology osce slides
Dermatology osce slidesDermatology osce slides
Dermatology osce slides
 
Gonorrhea
GonorrheaGonorrhea
Gonorrhea
 
Sexually transmitted diseases (pictures)
Sexually transmitted diseases (pictures)Sexually transmitted diseases (pictures)
Sexually transmitted diseases (pictures)
 
neisseria-gonorrhoeae
neisseria-gonorrhoeaeneisseria-gonorrhoeae
neisseria-gonorrhoeae
 
Presentaciòn Mycoplasma
Presentaciòn MycoplasmaPresentaciòn Mycoplasma
Presentaciòn Mycoplasma
 
Clamídia
ClamídiaClamídia
Clamídia
 
Mycoplasma complete
Mycoplasma completeMycoplasma complete
Mycoplasma complete
 
Treponema Pallidum - Microbiología
Treponema Pallidum - MicrobiologíaTreponema Pallidum - Microbiología
Treponema Pallidum - Microbiología
 
5 Cures for Chlamydia You Should Know!
5 Cures for Chlamydia You Should Know!5 Cures for Chlamydia You Should Know!
5 Cures for Chlamydia You Should Know!
 

Similar to Adolescent sti ucaya

Adolescent sti
Adolescent stiAdolescent sti
Adolescent stiUCAYAofSC
 
pid.pptx
pid.pptxpid.pptx
pid.pptx
BetelhemTegegn
 
Vulvovaginitis2
Vulvovaginitis2Vulvovaginitis2
Vulvovaginitis2
Israel vasquez
 
management of common STIs at primary care level.pptx
management of common STIs at primary care level.pptxmanagement of common STIs at primary care level.pptx
management of common STIs at primary care level.pptx
ADEC0023MOHDFAZLI
 
Pelvic inflammatory disease (PID)
Pelvic inflammatory disease (PID)Pelvic inflammatory disease (PID)
Pelvic inflammatory disease (PID)
Ali Kareem
 
SEXUALLY TRANSMITTED DISEASE.pptx
SEXUALLY TRANSMITTED DISEASE.pptxSEXUALLY TRANSMITTED DISEASE.pptx
SEXUALLY TRANSMITTED DISEASE.pptx
GOKUL J SIDDHARTH
 
Presentation1
Presentation1Presentation1
Presentation1
imral12345
 
Pelvicinflammatorydiseases chandni
Pelvicinflammatorydiseases chandniPelvicinflammatorydiseases chandni
Pelvicinflammatorydiseases chandni
ChandniThampi
 
sexual transmitted diseases and the emergency room
sexual transmitted diseases and the emergency room sexual transmitted diseases and the emergency room
sexual transmitted diseases and the emergency room
Rashid Abuelhassan
 
Urogenital infection in diabetic females
Urogenital infection in diabetic females Urogenital infection in diabetic females
Urogenital infection in diabetic females Mamdouh Sabry
 
pid-slides-2018.pptx
pid-slides-2018.pptxpid-slides-2018.pptx
pid-slides-2018.pptx
YousifAhmedDA
 
10. STI.pptx
10. STI.pptx10. STI.pptx
10. STI.pptx
TEWODROS64
 
GUM Basics & Cases
GUM Basics & CasesGUM Basics & Cases
GUM Basics & Cases
Mazin Eragat
 
Pelvic Inflammatory Disease
Pelvic Inflammatory DiseasePelvic Inflammatory Disease
Pelvic Inflammatory Disease
limgengyan
 
Sti ppt
Sti pptSti ppt
Sti ppt
naz khan
 
Mgt of PID.pptx
Mgt of PID.pptxMgt of PID.pptx
Mgt of PID.pptx
Aisha lamido
 
Pid by dr shabnam naz
Pid by dr shabnam nazPid by dr shabnam naz
Pid by dr shabnam naz
dr shabnam naz shaikh
 

Similar to Adolescent sti ucaya (20)

Adolescent sti
Adolescent stiAdolescent sti
Adolescent sti
 
pid.pptx
pid.pptxpid.pptx
pid.pptx
 
Vulvovaginitis2
Vulvovaginitis2Vulvovaginitis2
Vulvovaginitis2
 
Urethritis seminar
Urethritis seminarUrethritis seminar
Urethritis seminar
 
management of common STIs at primary care level.pptx
management of common STIs at primary care level.pptxmanagement of common STIs at primary care level.pptx
management of common STIs at primary care level.pptx
 
Pelvic inflammatory disease (PID)
Pelvic inflammatory disease (PID)Pelvic inflammatory disease (PID)
Pelvic inflammatory disease (PID)
 
SEXUALLY TRANSMITTED DISEASE.pptx
SEXUALLY TRANSMITTED DISEASE.pptxSEXUALLY TRANSMITTED DISEASE.pptx
SEXUALLY TRANSMITTED DISEASE.pptx
 
Presentation1
Presentation1Presentation1
Presentation1
 
Pelvicinflammatorydiseases chandni
Pelvicinflammatorydiseases chandniPelvicinflammatorydiseases chandni
Pelvicinflammatorydiseases chandni
 
sexual transmitted diseases and the emergency room
sexual transmitted diseases and the emergency room sexual transmitted diseases and the emergency room
sexual transmitted diseases and the emergency room
 
Urogenital infection in diabetic females
Urogenital infection in diabetic females Urogenital infection in diabetic females
Urogenital infection in diabetic females
 
pid-slides-2018.pptx
pid-slides-2018.pptxpid-slides-2018.pptx
pid-slides-2018.pptx
 
10. STI.pptx
10. STI.pptx10. STI.pptx
10. STI.pptx
 
Pid
PidPid
Pid
 
GUM Basics & Cases
GUM Basics & CasesGUM Basics & Cases
GUM Basics & Cases
 
Pid
PidPid
Pid
 
Pelvic Inflammatory Disease
Pelvic Inflammatory DiseasePelvic Inflammatory Disease
Pelvic Inflammatory Disease
 
Sti ppt
Sti pptSti ppt
Sti ppt
 
Mgt of PID.pptx
Mgt of PID.pptxMgt of PID.pptx
Mgt of PID.pptx
 
Pid by dr shabnam naz
Pid by dr shabnam nazPid by dr shabnam naz
Pid by dr shabnam naz
 

More from Greenville Health System

Sexperts sexual health ucaya
Sexperts sexual health ucayaSexperts sexual health ucaya
Sexperts sexual health ucaya
Greenville Health System
 
Prep and mksap sti presentation ucaya
Prep and mksap sti presentation ucayaPrep and mksap sti presentation ucaya
Prep and mksap sti presentation ucaya
Greenville Health System
 
Hpv in men ucaya
Hpv in men ucayaHpv in men ucaya
Hpv in men ucaya
Greenville Health System
 
Intro to adolescent medicine ucaya
Intro to adolescent medicine ucayaIntro to adolescent medicine ucaya
Intro to adolescent medicine ucaya
Greenville Health System
 
Hiv ucaya
Hiv ucayaHiv ucaya
Depression and anxiety screening ucaya
Depression and anxiety screening ucayaDepression and anxiety screening ucaya
Depression and anxiety screening ucaya
Greenville Health System
 
Adolescents and substance abuse ucaya
Adolescents and substance abuse ucayaAdolescents and substance abuse ucaya
Adolescents and substance abuse ucaya
Greenville Health System
 
Adolescent gynecology ucaya
Adolescent gynecology ucayaAdolescent gynecology ucaya
Adolescent gynecology ucaya
Greenville Health System
 
Adhd ucaya
Adhd ucayaAdhd ucaya

More from Greenville Health System (9)

Sexperts sexual health ucaya
Sexperts sexual health ucayaSexperts sexual health ucaya
Sexperts sexual health ucaya
 
Prep and mksap sti presentation ucaya
Prep and mksap sti presentation ucayaPrep and mksap sti presentation ucaya
Prep and mksap sti presentation ucaya
 
Hpv in men ucaya
Hpv in men ucayaHpv in men ucaya
Hpv in men ucaya
 
Intro to adolescent medicine ucaya
Intro to adolescent medicine ucayaIntro to adolescent medicine ucaya
Intro to adolescent medicine ucaya
 
Hiv ucaya
Hiv ucayaHiv ucaya
Hiv ucaya
 
Depression and anxiety screening ucaya
Depression and anxiety screening ucayaDepression and anxiety screening ucaya
Depression and anxiety screening ucaya
 
Adolescents and substance abuse ucaya
Adolescents and substance abuse ucayaAdolescents and substance abuse ucaya
Adolescents and substance abuse ucaya
 
Adolescent gynecology ucaya
Adolescent gynecology ucayaAdolescent gynecology ucaya
Adolescent gynecology ucaya
 
Adhd ucaya
Adhd ucayaAdhd ucaya
Adhd ucaya
 

Recently uploaded

Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
Jisc
 
Group Presentation 2 Economics.Ariana Buscigliopptx
Group Presentation 2 Economics.Ariana BuscigliopptxGroup Presentation 2 Economics.Ariana Buscigliopptx
Group Presentation 2 Economics.Ariana Buscigliopptx
ArianaBusciglio
 
A Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptxA Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptx
thanhdowork
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Sandy Millin
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
timhan337
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
Atul Kumar Singh
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
heathfieldcps1
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
TechSoup
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
JosvitaDsouza2
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
Celine George
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
Jisc
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
MysoreMuleSoftMeetup
 
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHatAzure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
Scholarhat
 
The French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free downloadThe French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free download
Vivekanand Anglo Vedic Academy
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 
STRAND 3 HYGIENIC PRACTICES.pptx GRADE 7 CBC
STRAND 3 HYGIENIC PRACTICES.pptx GRADE 7 CBCSTRAND 3 HYGIENIC PRACTICES.pptx GRADE 7 CBC
STRAND 3 HYGIENIC PRACTICES.pptx GRADE 7 CBC
kimdan468
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
EduSkills OECD
 

Recently uploaded (20)

Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
 
Group Presentation 2 Economics.Ariana Buscigliopptx
Group Presentation 2 Economics.Ariana BuscigliopptxGroup Presentation 2 Economics.Ariana Buscigliopptx
Group Presentation 2 Economics.Ariana Buscigliopptx
 
A Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptxA Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptx
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
 
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHatAzure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
 
The French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free downloadThe French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free download
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
 
STRAND 3 HYGIENIC PRACTICES.pptx GRADE 7 CBC
STRAND 3 HYGIENIC PRACTICES.pptx GRADE 7 CBCSTRAND 3 HYGIENIC PRACTICES.pptx GRADE 7 CBC
STRAND 3 HYGIENIC PRACTICES.pptx GRADE 7 CBC
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
 

Adolescent sti ucaya

  • 1. Sexually Transmitted Infections Mike Guyton, MD Assistant Clinical Professor/Academic Faculty in General Pediatrics
  • 2. Reportable STI’s in SC (2014) • Chancroid • Chlamydia trachomatis, genital site • Gonorrhea (include susceptibility profile) • (URGENT) Acute Hepatitis (A-E) • Chronic Hepatitis (B-D) • Hepatitis B Surface Antigen + with each pregnancy • HIV and AIDS Clinical Diagnosis and positive test results* • Lymphogranuloma Venereum • (URGENT) Syphilis (congenital, primary, secondary, latent, tertiary, positive test
  • 3. STI’s in the US • The US ranks first among developed nations in the rate of STI’s – In addition to teen pregnancies • 24% of adolescent females (14-19) have lab evidence of at least 1/5 STI’s – HPV (18%) – Chlamydia (4%) – Trichomonas (3%) – HSV 2 (2%) – Gonorrhea • Repeated STI infection is a recognized risk factor for development of HIV infection – 3X higher in students with h/o multiple gonorrhea infections vs. no infections
  • 4. Quick CDC Facts • FACT: 19 million new infections occur every year in the US • FACT: STI’s cost the US HealthCare System $17 billion yearly • FACT: Untreated STI’s cause 24,000 women in the US to become infertile yearly • FACT: While young people only represent 25% of the sexually experienced population in the US, they account for almost 50% of newly diagnosed STI infections • FACT: ~20% of adolescents fail to fill Rx for STI treatment
  • 5. Specific To Adolescents Risk Factors • Behavioral – Time elapsed since first intercourse – Multiple or new partners – Inconsistent use of condoms – Alcohol/drug use* • Biologic – Cervical ectopy/immaturity – Low levels of sIgA Unique Issues • Self-consent for Dx and Tx • Concerns about privacy and confidentiality • Pregnancy/fear of pregnancy • Self-treatment • Preference to notify partners themselves
  • 6. Expedited Partner Therapy • Approach where partners who test positive for certain STI’s are given RX without previous medical evaluation • Recommended use from CDC since 2006 • Previously recommended for Gonorrhea and Chlamydia; however Gonorrhea recs have changed – Difficult to give due to new recommendations for ceftriaxone injection only! • EPT is permissible in SC and NC – Visit www.cdc.gov/std/ept/legal/default.htm
  • 7. STI Clinical Patterns • Discharge Syndromes – Gonorrhea and Chlamydia – Bacterial Vaginosis/Candidiasis – Mycoplasma Genitalium • Genital Ulcer Syndromes – Herpes Simplex Virus – Primary Syphilis – Chancroid/Lymphogranuloma Venereum/ Granuloma Inguinale • Pelvic Inflammatory Disease • Dermatologic Syndromes – HPV – Secondary Syphilis – Disseminated Gonococcal Infection – Pediculosis Pubis
  • 8. Chlamydia and Gonorrhea • Chlamydia is the most common bacterial STI in men and women – Cervicitis (not vaginitis) with menometrorrhagia – Dysuria-Pyuria Syndrome – PID – Perihepatitis – Proctitis – Men: See Urethritis, Prostatitis, Proctitis, Epididymitis, Reactive Arthritis (1%) • Gonorrhea – Similar to above, but also can see higher incidence of pharyngitis (1- 12%) – While mucoprulent discharge common, asymptomatic cases also occur (50% in women vs 10-15% in men)
  • 9. Chlamydia and Gonorrhea: Treatment • Gonorrhea: – Ceftriaxone 250mg IM x 1 PLUS Azithromycin 1g po x 1 OR Doxycycline 100mg po BID x 7 days – Other: • ceftizoxime 500 mg intramuscularly/ cefotaxime 500 mg intramuscularly/cefoxitin 2 g intramuscularly PLUS Azithro or Doxy • Oral Cefixime 400mg x 1 dose PLUS Azithro OR Doxy • Azithromycin Monotherapy with 2g x 1 dose • Chlamydia: – Azithromycin 1g po x 1 dose – Doxycycline 100mg po BID x 7 days – Other: • Ofloxacin 300 mg orally twice daily for seven days • Levofloxacin 500 mg orally once daily for seven days • Erythromycin/PCN if pregnant and intolerant to Azithro
  • 10. Rescreening • “Rescreen all adolescents infected with chlamydia or gonorrhea 3 months after treatment, regardless of whether they believe that their sex partners were treated.”
  • 11. Bacterial Vaginosis/Candidiasis • Bacterial Vaginosis: – Most common cause of vaginal discharge in women of childbearing age (40-50%); abnormal alteration of vaginal flora – Tx: Metronidazole 500mg po BID x 7 days OR Metronidazole Gel 0.75% qday x 5 days OR Clindamycin 2% cream qhs x 7 days – Other • Clindamycin 300mg po x 7 days; Clindamycin Ovule; Tinidazole • Candidiasis: – Common in healthy reproductive age women; less likely sexual transmission; often clinical diagnosis – Tx: Recommended: Fluconazole 150mg po x 1 dose or if severe/complicated, 150mg po every 72h x 2-3 doses.
  • 12. Mycoplasma Genitalium • Causes Non-Gonococcal Urethritis in men and emerging cause of cervicitis and PID in women – 15-25% of cases of NGU in men – 18-46% of cases of NCNGU in men – Role in women not fully established • Co-infections with other STI-causing organisms is highly reported • Clinical: – Men: usually symptomatic (as high as 70%) with discharge, balantitis, or posthitis – Women: usually asymptomatic or occur with symptoms of PID • Treatment: – Empiric: Azithromycin OR Doxycycline – Targeted: Same as above; Moxifloxicin if persistent infection/symptoms
  • 13. PREP Question • An 18-year-old woman has a 3-day history of fever, headache, and painful sores in the genital area. The patient has no previous history of genital lesions. Medical history is unremarkable, and her only medication is an oral contraceptive agent. She does not use condoms. On physical examination, temperature is 38.1 °C (100.6 °F); other vital signs are normal. There are no signs of meningismus. Tender ulcerative lesions with a yellow crusted roof cover the labia bilaterally and the vaginal introitus. • A.) Chancroid • B.) Genital Herpes Simplex Virus Infection • C.) Primary Syphilis • D.) Vulvovaginal Candidiasis
  • 14. PREP Question • An 18-year-old woman has a 3-day history of fever, headache, and painful sores in the genital area. The patient has no previous history of genital lesions. Medical history is unremarkable, and her only medication is an oral contraceptive agent. She does not use condoms. On physical examination, temperature is 38.1 °C (100.6 °F); other vital signs are normal. There are no signs of meningismus. Tender ulcerative lesions with a yellow crusted roof cover the labia bilaterally and the vaginal introitus. • A.) Chancroid • B.) Genital Herpes Simplex Virus Infection • C.) Primary Syphilis • D.) Vulvovaginal Candidiasis
  • 15. Genital Herpes • Belongs to the Genital Ulcer Syndromes – HSV, T. pallidum, and H. ducreyi • HSV2 is predominant, with increasing HSV1 genital occurrence in females • Lesions begin as vesicles, which then rupture to form painful ulcers – Usually occurring as clusters • Occurs as a Primary Outbreak, Recurrent Outbreak, and Latent Infection – Primary outbreak last 2-3 weeks and often associated with systemic symptoms (fever, malaise, dysuria) – Recurrent Outbreaks usually are shorter, 7-12 days • HSV has a high infectivity and high recurrence rate – Infectivity 75-80% with active infection – HSV1 Recurrence: 60%; HSV2 Recurrence: 90%
  • 16. Genital Herpes: Treatment • Treatment differs based on type of infection – Primary: • Acyclovir 400mg po TID or 200mg po 5x/d x 7- 10 days • Famciclovir 250mg TID x 7-10 days • Valacyclovir 1g BID x 7-10 days – Recurrent: • Acyclovir 800mg TID x 2 days or BID x 5 days • Famciclovir 1g BID x 1 day or 125mg BID x 5 days • Valacyclovir 500mg BID x 3 days – Suppression: • Valacyclovir 1g po qday (can be 500mg daily if <9 recurrences/year) – 500mg BID if immunoompromised
  • 17.
  • 18. Primary Syphilis • After incubation, a ulcerating, painless papule occurs at site of inoculation; heal 3-6 weeks later • Usually singular, but can be multiple in setting of HIV • Associated with regional mild-moderate bilateral LAN • Secondary Syphilis can occur weeks to months later
  • 19. Syphilis: Treatment • Primary, Secondary, or Latent <1 year – PCN G Benzathine 2.4 million units IM x 1 – Doxycycline 100mg po BID x 7 days • Jarish-Herxheimer Reaction – Acute febrile reaction with HA and myalgias in first 24 hours of treatment
  • 20. Chancroid/Lymphogranuloma Venereum/Granuloma Inguinale • Chancroid – Haemophilus ducreyi, very uncommon in the US – Papule  pustule  PAINFUL ulcers with fluctuant buboes (lymph nodes can spontaneously rupture) – Tx: Azithromycin 1g po x 1 OR Ceftriaxone 250mg IM x 1 • Lymphogranuloma Venereum – L1, L2, and L3 serovars of Chlamydia; tropical and subtropical areas of the world – Spontaneously healing PAINLESS genital ulcer extension to regional lymph nodes (groove sign)  fibrosis and stricture of anogenital tract – Tx: Doxycycline 100mg po BID x 21 days OR Erythromycin/Azithromycin • Granuloma Inguinale (Donovanosis) – Uncommon, caused by Klebsiella granulomatis (PAINLESS ULCER[S]) – Tx: Doxycycline, Azithromycin, Cipro, Erythromycin, or Bactrim x 3 weeks
  • 21.
  • 22. Pelvic Inflammatory Disease • Acute infection of the upper genital tract of women – Chlamydia, Gonorrhea, or Vaginal Flora organisms (Anaerobes and GNR) – RF for subsequent ectopic pregnancy and infertility • Clinical Diagnosis of PID is often imprecise; need evaluation of risk factors – Lower Quadrant Abdominal Pain, acute in nature – Abnormal uterine bleeding (1/3 of patients) – New onset discharge, urethritis, Proctitis, fever (non-specific) • Empiric Treatment often initiated if 1 out of three clinical findings present (in the setting of abdominal pain): – Cervical Motion Tenderness – Uterine Tenderness – Adnexal Tenderness
  • 23. Pelvic Inflammatory Disease: Treatment Indications for Hospitalization • Pregnancy • Nonresponse/tolerance to po medications • Noncompliance • Inability to take oral medications • Severe clinical illness (high fever, nausea, vomiting, severe abdominal pain) • Complicated PID with pelvic abscess • Possible need for surgical intervention or diagnostic exploration for alternative etiology (e.g., appendicitis) Outpatient vs Inpatient • Outpatient: – Ceftriaxone 250mg IM x 1 PLUS Doxy 100mg po BID x 14 days – Cefoxitin 2mg IM with Probenecid 1g po x 1 PLUS Doxy 100mg po BID x 14 days • Inpatient: – Cefoxitin (2g IV q6) OR Cefotetan (2g IV q12) PLUS Doxy100mg po q12 – Clindamycin 900mg IV q8 PLUS Gentamicin (Load: 2mg/kg; Maint: 1.5mg/kg q8)
  • 24. Genital Warts • Condyloma Accuminata, caused by Human Papilloma Virus – >70 different subtypes; High risk associated with cancers (16, 18) and low risk associated with genital warts (6, 11) – Incubation is 3w-8m and most infections are cleared within 2 years • Risk Factors – Sexual activity (more partners increases the risk in Men and Women) – Concomitant/history of recurrent STI’s – Individuals who are HIV positive • Clinical – Ranges from asymptomatic (M and F) to problematic, depending on the size of warts – Can see Pruritus, pain, bleeding, tenderness, or vaginal discharge • Differential Diagnosis – Condyloma Lata – Micropapillomatosis – Pearly Penile Papules – Squamous Cell Carcinoma
  • 25. Genital Warts: Treatment • Multiple Modalities of Treatment – Spontaneous Remission (20-30% of cases) – Chemical Agents • Podophyllin: Teratogenic, risk of chemical burns • Trichloroacetic Acid: can be used internally, but highly caustic • 5-Fluorouracil Epinephrine Gel: Injected Intralesionally – Immune Modulation • Imiquimod: Complete clearance rates of 40-70% with few recurrence • Interferon Alfa: side effects of interferon • Sinecatechins: botanical – Surgery • Cryotherapy, Laser, Excisional – HPV Vaccination: highly effective
  • 26.
  • 28. Disseminated Gonococcus • 0.5-3% of those infected with Nisseria gonorrheae (M>F 3X) • Certain Risk Factors Exist – Recent menstruation, Pregnancy/immediate post-partum, complement deficiencies, or SLE • Clinical Findings: – Triad: Tenosynovitis, dermatitis, polyarthralgias without purulent arthritis • Acute Fever, chills, malaise is heralding • Lesions often painless, pustular or vesiculopustular – Purulent arthritis without skin lesions • Asymmetric, usually knees/wrists/ankles • Treatment: – Ceftriaxone 1g q24 hours initially PLUS Azithromycin 1g po x 1 OR Doxycycline 100mg po BID x 7 days – Duration: 7-14 days; step down therapy controversial
  • 30. Pediculosis Pubis • Crab Louse, transmitted through sex or sometimes Fomites • Clinical: – Itching – Maculae Cerulae: pale blue macules (0.5-1cm) from the anticoagulant present in saliva of parasite, prolonged infestation – Sometimes LAN • Treatment: – Permethrin 1% cream applied and washed off after 10 minutes – Pyrethrins with piperonyl butoxide, same as above – Alternative • Malathion 0.5% lotion applied and washed off after 8-12 hours • Ivermectin 250mcg/kg orally x 1, repeated in 1-2 weeks • Lindane not recommended
  • 32. A word on HIV screening • Test: HIV Ag/Ab Combo • CDC Recommendations: – Opt-Out HIV testing for all patients 13-64 years old • AAP Recommendations: – Routine HIV testing to be offered at least once to all adolescents (despite report of sexual activity) by 16-18yo in clinic settings where HIV prevalence is >0.1% – Prevalence <0.1%: HIV testing for all sexually active adolescents and those with other risk factors

Editor's Notes

  1. *and many labs related to the HIV diagnosis, such as CD4 results, subtype/genotype/phenotype, viral load, receptor assays
  2. -Gonorrhea acquisition decreased slightly among adolescent females in 2011-2012
  3. -In an observational study in adolescent females, ~25% were diagnosed with an STD within 1 year of first intercourse, particularly for HPV -Inconsistent condom use particularly a concern when partners become established -Alcohol/drugs may not be an independent risk factor, as this can track with poor contraceptive use or multiple partners -2011 Youth Risk Behavior Survey (high school students): 47% ever had intercourse, 34% currently sexually active, 15% intercourse with >4 partners in lifetime, 60% reported condom use at last intercourse -Columnar Epithelium is thought to be more susceptible than squamous epithelium to STI organisms -Adolescent females with slightly lower IgA levels than adult women in one small study -Self treatment reported by as much as 25% of adolescents with STD’s. Topical meds, Abx, or douching. Take about females 10 days on avg to seek care vs 6 days for males
  4. -Not all genital ulcers are STI’s; Non-sexually transmitted ulcers (Lipschutz Ulcers, Virginal Ulcers, Aphthous Ulcers) can be seen with vital illness, Bechet’s disease, Crohn’s Disease, or other Vasculidities
  5. Pharyngitis depends on women vs men, and if MSM; can also be colonization -Menometrorrhagia: prolonged/excessive uterine bleeding occurring irregularly and with increased frequency -Cervicitis: inflammation of the cervix -Vaginitis: inflammation of the vagina (more associated with Candidiasis, Trichomonas, and BV) -Strawberry Cervix with Trichomonas from capillary dilatation, not cervicitis
  6. -Coinfection of Gonorrhea with Chlamydia as high as 46% in men and women -Note: increased resistance to Doxycycline reserves its use for only Azithro-intolerant patients -Test of Cure (Gonorrhea) needed ~1 week after treatment if Azithro monotherapy or Oral cephalosporin therapy used; Chlamydia only needs TOC if pregnant or has persistent symptoms. -With Chlamydia and signs of Proctitis or Epididymitis, also treat for Gonorrhea; Pharyngeal suspicion needs a positive culture
  7. Providers should consider rescreening females previously diagnosed with trichomoniasis 3 months after treatment. If retesting at 3 months is not possible, retest whenever patients next present for health care services in the 12 months after initial treatment.
  8. BV: reduction in lactobacillus (H2O2 producing prevents bacterial overgrowth), The major bacteria detected are Gardnerella vaginalis (normal flora) and detection is increased in sexually active young women -Sex activity is a risk factor for BV, and most believe it does not occur in those who have never had sex -Condoms and estrogen-containing contraceptives appear to be protective -Thin fishy discharge, 50-75% asymptomatic Candida: Recurrent Infection is 4 or more times in 1 year, culture needs to be obtained; can be seen in HIV but not an indication for screening -10-20% of women are asymptomatic and don’t need treatment -Many treatments available -Other causes of Vaginitis: Peptostreptococcus, Bacteroides
  9. -can also see causing persistent/recurring cases of urethritis in men -Dx only through NAAT (not widespread available)
  10. Chancroid: Haemophilus ducreyi. Painful ulcer with irregular borders. Epidemics associated with prostitution and drug use. More in underdeveloped countries.
  11. -Primary infection is most often symptomatic, but can be asymptomatic in some patients -Viral culture of the lesion is diagnostic test of choice; serum PCR studies are also available. -Triggers of recurrent infections can include fever, menstruation, stress, or friction
  12. -Aim to start treatment within 72 hours of the lesion occurrence to decrease duration and potential for complications Side Effects: GI symptoms, HA with acyclovir/Valtrex Other Suppression: Acyclovir 400mg po BID, Famciclovir 250mg BID
  13. -High Risk Populations: Sex Workers, Cocaine Users, and MSM -Secondary Syphilis: may no be associated with a primary chancre, constellation of symptoms including palmar/sole rash, fever/malaise/HA/sore throat, LAN (post cervical, axillary, inguinal, and femoral regions), “moth eaten” alopecia, hepatitis, GI/MSK/Renal abnormalities, neurosyphilis
  14. -LGV has a high association with HIV infection
  15. Factors that potentially facilitate PID include: Previous episode of PID Sex during menses Vaginal douching Bacterial Vaginosis Intrauterine device The most specific criteria for diagnosing PID include: endometrial biopsy with histopathologic evidence of endometritis; transvaginal sonography or magnetic resonance imaging techniques showing thickened, fluid-filled tubes with or without free pelvic fluid or tubo-ovarian complex, or Doppler studies suggesting pelvic infection (e.g., tubal hyperemia); or laparoscopic abnormalities consistent with PID. Lab tests: Pregnancy Test, CBC, Vaginal discharge GS and micro, GC/Chlamydia, U/A, CRP, HIV, Hepatitis B profile, RPR
  16. Alternative IP: Unasyn + Doxy, Azithro only, Azithro + Flagyl, Azithro + beta lactam Alternative OP: use recommended with or without flagyl, can use azithromycin instead of Doxy -Duration is usually 14 days -Probenecid is synergistic with Cefoxitin, improves efficacy
  17. -Can also be transmitted by fomites, but this is not the predominate mode of transmission
  18. Other: Topical Cidofovir, Bacillus Calmette-Guerin, Infrared Coagulation Overall recurrence rates of 30-70% within 6 months, depending on the form used -Imiquimod can not be used internally
  19. -Overlap exists between the two stages -Some suggest step down to cefixime, Cipro, Amox, or Doxy to finish course (only if sensitivities have been established) -If recurrent episodes, screen for complement deficiency
  20. -No resistance has been seen or noted in past, sexual contacts need to be treated, household contacts who are asymptomatic do not need to be treated. -Permethrin = Elimite, Acticin, NIX -Pyrethrins = RID, Pronto, Licide -Malathion = Ovide -Ivermectin = Sklice -Lindane = associated with hypersensitivity, neurologic toxicity, not a first choice agent
  21. -Opt-Out: informing the patient, orally or in writing, that HIV testing will be performed unless he/she declines -Annual HIV testing for high risk adolescents (IV Drug Use, Sex for Money, Multiple Partners, MSM) -Testing for other STD’s = test for HIV